Product Reports Resources Pricing Login Book a demo

Novacea

Biotech & Life Sciences · San Francisco, United States · Founded 2001

Valuation $100–500M
Headcount <100
Total funding $50–100M
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Novacea and the history behind them.

Company overview

Novacea company information

The essential company record, classifications and operating signals in one place.

Status
Acquired
Founded
2001
Headquarters
San Francisco, United States
Employees
13
Open positions
None listed
Dealroom signal
18.0
LinkedIn ↗
sub industryPharmaceuticalbusiness modelManufacturingindustryHealthsectorBiotechnologysectorSpinoutsectorBiotech and PharmasectorHard TechsectorDT and LSsectorscience-basedclient focusb2b

Valuation & funding

Novacea funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Feb 2009 $0 — Transcept Pharmaceuticals ↗
SERIES COther financing Jan 2004 $35M $140M NEA · Versant Ventures · Domain Associates · Apax Partners —
SERIES BOther financing Nov 2002 $36M $144M NEA · ProQuest Investments · Versant Ventures · Domain Associates —
SPINOUTOther financing Jan 2001 $0 — University of Pittsburgh ↗
Showing 4 recorded eventsUnlock the complete deal history →

Growth signals

Novacea team growth

Novacea's team grew 8.3% over the past year.

1-year team growth+8.3%
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Novacea compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Teitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases Aarhus, Denmark Operational 25 $31M $123M
Tay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise Dundee, United Kingdom Operational
XilisDeveloping next generation technologies for precision medicine and drug discovery Durham, United States Operational
PulmobioticsDiscovers and develops novel treatments and vaccines for respiratory diseases Barcelona, Spain Operational
Amphista TherapeuticsNext-generation therapeutics for targeted protein degradation Great Abington, United Kingdom Operational
CV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments Belfast, United Kingdom Operational
Nucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine Oxford, United Kingdom Operational
Asgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming Lund Municipality, Sweden Operational
Showing 8 of the closest matchesCompare every metric →

Talent graph

Novacea's talent

Book a demo to see the people
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on Novacea's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 4 investors entered at this stage
NEA
ProQuest Investments
Versant Ventures
Domain Associates
Series B+ 1 investor entered at this stage
Apax Partners
Other known 2 additional known investors
Transcept Pharmaceuticals
University of Pittsburgh

Global footprint

Where Novacea has talent and traffic

Workforce by country
🇺🇸 United States · San Francisco HQ
Book a demo for the full country breakdown

In the news

Latest news about Novacea

Recent press, funding announcements, and product moves mentioning Novacea — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Novacea

An AI-synthesized read of the highest-engagement posts about Novacea on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Novacea’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.